Keita Kudo

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba et al. · JAMA Oncology · 2017 · 1K citations

Pharmacy, Oncology, Pharmacotherapy +17

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi et al. · Journal of Thoracic Oncology · 2017 · 227 citations

Medicine, Oncology, Pharmacology +14

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kimio Yonesaka, Koji Haratani, Shiki Takamura et al. · Clinical Cancer Research · 2018 · 169 citations

Medicine, Immunology, Oncology +17

Detection of epidermal growth factor receptor T790M mutation in plasma <scp>DNA</scp> from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

Kazuko Sakai, Atsushi Horiike, Darryl Irwin et al. · Cancer Science · 2013 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Kimio Yonesaka, Keita Kudo, Satomi Nishida et al. · Oncotarget · 2015 · 66 citations · Full text

Medicine, Oncology, Pharmacology +14